Occurrence of de novo ABL kinase domain mutations in primary bone marrow cells after BCR-ABL gene transfer and Imatinib mesylate selection.
Flamant
S
S
Turhan
A G
AG
D000818:Animals; D001549:Benzamides; D001854:Bone Marrow Cells / Q000201:enzymology*; D016044:Fusion Proteins, bcr-abl / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D018014:Gene Transfer Techniques; D006801:Humans; D000068877:Imatinib Mesylate; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation / Q000187:drug effects / Q000235:genetics; D010879:Piperazines / Q000494:pharmacology*; D011505:Protein-Tyrosine Kinases / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D019076:Transgenes / Q000235:genetics
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl